Understanding and documentation of drug–drug interactions (DDIs) are an important
component of drug development, and of clinical therapeutics. Because clinical DDI studies …

Drug–drug interactions (DDIs) are an important clinical and public health concern. Although
DDI screening now occurs during drug development, it is difficult to predict clinical …

A common definition of interactions is when the effects of one drug are changed by the
presence of another drug, food, herbal medicine, or other exogenic substances. As a …

Drug interactions (DIs) may result in adverse drug events that could be prevented, but in
many cases the available information on potential DIs is not easily transferable to clinical …

Drug development involves learning and confirming in healthy volunteers and ultimately in
patients. This approach should apply to drug–drug interactions because requirements to …

In 2009, the current authors founded a focused meeting dedicated to regulatory
requirements and scientific aspects of preclinical and clinical investigations of drug–drug …

Drug interactions are ubiquitous but those with proven clinical relevance are much less
common. Only when the combined effects of the interacting drugs are greater or less than …

Background: In practice the benefit of cardiovascular medicines is less consistent than it is in
clinical trials. This is due to multiple uncontrolled factors that co-determine the efficacy of the …

In October 2009, a 2‐day, multistakeholder, national conference was held in Rockville,
Maryland, to discuss and propose methods to improve the drug‐drug interaction (DDI) …

The potential importance of drug-drug interaction (DDIs) is increasing as polypharmacy
becomes more and more prevalent. In vitro data cannot directly predict clinical DDIs, but …